Abstract
Tenofovir disoproxil fumarate has rapidly become an integral part of HIV antiretroviral regimens throughout the world. The advancement of increasingly effective therapeutics has led to a new frontier in HIV treatment, notably the search for options that retain high potency but improved tolerability and long-term safety profiles. Tenofovir alafenamide is a new investigational prodrug developed by Gilead Sciences, Inc. Tenofovir alafenamide has enhanced tissue distribution, specifically into lymphoid tissue, providing increased delivery of active drug to the target site of viral replication. This property may enhance drug activity and allow for a lower required oral administered dose, lower plasma drug levels and reduced adverse effects on the kidney and bone.
Original language | English (US) |
---|---|
Pages (from-to) | 1069-1075 |
Number of pages | 7 |
Journal | Future Virology |
Volume | 10 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2015 |
Keywords
- HBV
- HIV
- antiretroviral
- tenofovir
ASJC Scopus subject areas
- Virology